Becton Dickinson (NYSE: BDX) today launched the first automated phenotypic diagnostic test for infections caused by carbapenemase-producing organisms.
The new BD Phoenix CPO test is available as part of the BD Phoenix automated microbiology system in Europe, the company said, and is designed to help hospitals detect and contain infections caused by CPOs.
Get the full story at our sister site, Drug Delivery Business News.
The post BD launches fully-automated diagnostic to fight antimicrobial resistance in Europe appeared first on MassDevice.
from MassDevice http://ift.tt/2hvVlbH
Cap comentari:
Publica un comentari a l'entrada